Palo Alto, United States
OrsoBio, founded in 2021, is a United States-based, clinical-stage biopharmaceutical company aiming to transform the treatment of severe metabolic disorders. Guided by its slogan, "Advancing first-in-class therapies to restore energy homeostasis", the company focuses on innovative treatments for conditions such as type 2 diabetes and nonalcoholic steatohepatitis.
With four programs currently in clinical and preclinical development, OrsoBio is leveraging first-in-class compounds targeting central energy metabolism pathways, positioning itself at the cutting edge of the Biopharma, Biotechnology, and Health Care industries.
In a recent funding milestone, OrsoBio secured a $60.00M Series A investment on 07 November 2023. This significant backing from esteemed investors such as Longitude Capital, Eli Lilly, Enavate Sciences, Samsara BioCapital, and NuevaBio, underscores investor confidence in the company's mission and innovative approach.
